Table 2.

Plasma free sialic acid (Neu5Ac) levels in subjects with diverse eGFR

SubjectAge(yr)SexeGFRa(ml/min per 1.73 m2)Plasma Free Neu5AcSerum Creatinine(mg/dl)Serum Albumin(g/dl)Urine Creatinine(mg/dl)Urine Protein(mg/dl)Urine Albumin(mg/L)UPCR(mg/mg)UACR(mg/g)
(ng/ml)(µM/L)
MCD128M922040.6601.095.11581214.90.0769.4
FSGS147F823101.0020.843.517667350303.8242858
FSGS236M793691.1931.323.610435830343.4422917
FSGS358M613451.1161.283.3331178473.5452567
GN1b46M603531.1411.394.4391485.90.359220.3
FSGS442F563441.1121.353.534442931.294862
ANCA1c27F463171.0251.524.122332731881.6681429.6
FSGS574M356292.0341.853.64438126708.6596068
FSGS637M306772.1892.914.38417513612.0831620.2
FSGS7d45M296031.9502.753.712150937764.2073120
MN165M288192.6482.871.517018101266210.6477448.2
FSGS839M274311.3942.343.67167346549.4796555
FSGS949M265091.6462.683.9451319232.9112051.1
IgA168F205461.7652.354.54849293.41.021611.3
FSGS1074F148512.7523.484.59530519343.2112035.8
FSGS1153M812604.0748.364.86174403.41.213661.3
Normal range>90100–2000.32–0.650.5–1.23.5–5.215–3920–140–20.90.001–0.16<30
GNEM-137M1551790.579
GNEM-232M1491140.369
GNEM-347M1461380.446
GNEM-4e36F1431210.391
GNEM-5e36F1431750.566
GNEM-632M1411340.433
GNEM-7e49M1371290.417
GNEM-832M1351160.375
GNEM-930F1311290.417
GNEM-1047F1191090.352
GNEM-11e51F1162060.666
GNEM-12e51F1101670.534
GNEM-1353F1081730.559
GNEM-1454M1051400.453
GNEM-15e49M1051410.456
GNEM-1635F1051660.537
GNEM-1730F951210.391
GNEM-1865M951800.582
GNEM-1950F952000.647
GNEM-2044F921420.459
GNEM-2139F901820.588
GNEM-2252M851640.530
  • Neu5Ac, N-acetylneuraminic acid/sialic acid; UPCR, urine protein-creatinine ratio; UACR, urine albumin-creatinine ratio; MCD, minimal change disease; M, male; F, female; MN, membranous nephropathy; IgA, IgA nephropathy; GNEM, GNE myopathy; CKD-EPI, CKD Epidemiology Collaboration; p-ANCA, perinuclear ANCA.

  • a Note that eGFR was estimated using the CKD-EPI creatinine/cystatin C equation for subjects with glomerular disease, and using the CKD-EPI cystatin C equation for subjects without kidney disease (12).

  • b Mesangial proliferative GN.

  • c p-ANCA vasculitis.

  • d Collapsing FSGS.

  • e In three subjects, plasma free Neu5Ac and eGFR were assessed twice, at least 3 mo apart. Although these three samples were from the same subjects, they were included in our assessment because they were collected under different circumstances. The following subject numbers represent the same individual: GNEM-4 and GNEM-5; GNEM-11 and GNEM-12; GNEM-7 and GNEM-15.